
    
      A Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group,
      Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and
      Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599,
      When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of
      Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects
      with Known Risk Factors for PONV Who are Undergoing Surgical Procedures Associated with an
      Increased Emetogenic Risk
    
  